ESGCT 2025 | Cytiva

At #ESGCT2025, the future of cell and gene therapy is taking center stage, and Aaron got the inside scoop from two leaders driving it forward: Suha Zwayen, PhD, leading Cytiva’s nanomedicine business unit across EMEA, and Claudia Gagliardini, heading Cytiva’s gene therapy business unit across EMEA.

During their chat, they unpacked the latest trends, from in vivo cell therapies to personalized cancer vaccines, and shared why ESGCT is more than a conference—it’s a vibrant community where ideas, connections, and a little friendly competition come together.

Full of energy and inspiration, this conversation highlights innovation, collaboration, and the power of building lasting connections.